---
title: "Wall Street's bull case for Bristol Myers Squibb is getting louder"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299558994.md"
description: "The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns."
datetime: "2026-09-20T13:54:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299558994.md)
  - [en](https://longbridge.com/en/news/299558994.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299558994.md)
generator: "portal-rs"
---

# Wall Street's bull case for Bristol Myers Squibb is getting louder

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb secures expanded US approval for Camzyos](https://longbridge.com/en/news/300671144.md)
- [Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma](https://longbridge.com/en/news/300139167.md)
- [Bristol Myers Squibb (BMY) Doubles MRD‑Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM](https://longbridge.com/en/news/300139432.md)
- [FACTBOX-US drugmakers turn to China for licensing deals](https://longbridge.com/en/news/300320607.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**